Studienindikation: Rheumatoide Arthritis
Phase:
Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing
Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic
Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With
Moderately to Severely Active Rheumatoide Arthritis With Inadequate
Response or Intolerance to Biologic DMARDs (bDMARDs)
EudraCT-Number: 2015-003335-35
Studienindikation: Rheumatoide Arthritis
Phase:
Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing
Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX)
Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active
Rheumatoide Arthritis
EudraCT-Number: 2015-003334-27
Studienindikation: Rheumatoide Arthritis
Phase:
Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing
Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to
Severely Active Rheumatoide Arthritis Who Are on a Stable Dose of
Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs
(csDMARDs) and Have an Inadequate Response to csDMARDs
EudraCT-Nummer: 2015-003332-13
Studienindikation: Rheumatoide Arthritis
Phase:
Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing
Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With
Moderately to Severely Active Rheumatoide Arthritis Who Are on a
Stable Background of Methotrexate (MTX) and Who Have an Inadequate
Response to MTX (MTX-IR)
EudraCT-Nummer: 2015-003333-95
Studienindikation: Rheumatoide Arthritis
Phase:
Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing
Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Subjects
With Moderately to Severely Active Rheumatoide Arthritis With
Inadequate Response to MTX
EudraCT-Nummer: 2015-003376-75